In acute brain injury syndromes, the potent N methyl-o-aspartate (NMDA) antagonist, MK-801, can pre vent neuronal degeneration, and the general anesthetics, isoflurane and propofol, may also provide neuroprotective benefits, An obstacle to the use of NMDA antagonists for neuroprotective purposes is that they can cause a neuro toxic vacuole reaction in cerebrocortical neurons, This study demonstrates the ability of isoflurane and propofol to prevent the neurotoxic vacuole reaction induced by MK-801, Low sedative doses of inhaled isoflurane (1 %) or intraExcessive activation of excitatory receptors by the endogenous transmitter, glutamate, is believed to trig ger neuronal degeneration in commonly occurring acute brain or spinal cord injury syndromes (stroke, trauma, hypoglycemia, status epilepticus) (Choi, 1988) . The N-methyl-D-aspartate (NMDA) subtype of gluta mate receptor is thought to play a major role in the neurodegenerative process, based on evidence that NMDA receptor antagonists are neuroprotective in various experimental models of acute brain or spinal cord injury (Faden et aI., 1989; McCulloch, 1992) , A potential obstacle to the use of NMDA antago nists for neurotherapeutic purposes is the fact that these agents cause psychotomimetic reactions in adult humans (Luby et aI
can injure or kill cerebrocortical neurons in the adult rat brain. At low doses, NMDA antagonists cause a reversible vacuole reaction in pyramidal neurons of the posterior cingulate and retrosplenial (PC!RS) cortex (Olney et aI., 1989) , but at higher doses, PC! RS neurons are killed (Fix et aI., 1993; Corso et aI., 1994) . In order for NMDA antagonists to be of opti mal value as neuroprotective agents, it will be neces sary to develop strategies for counteracting or avoid ing these side effects.
Ketamine, an NMDA antagonist that has been used in human anesthesia for two decades, causes psychotic ("emergence") reactions in human adults that are reduced in frequency and severity by co administration of either of two classes of drugs benzodiazepines or barbiturates-that facilitate y aminobutyric acid (GABAA) receptor-mediated neurotransmission (Magbagbeola and Thomas, 1974; Reich and Silvay, 1989) . It has been shown that these two classes of drugs also prevent the neurotoxic vacu ole reaction induced in rat cerebrocortical neurons by the powerful NMDA antagonist, MK-801 (Olney et aI., 1991) . Based on this and other related evidence, it has been proposed that a GABAA receptor mediated disinhibition mechanism underlies both the psychotic and neurotoxic side effects of NMDA an-tagonists (Olney and Farber, 1995) . Further support ing this proposal is the recent finding by Ishimaru et ai. (1995) that halothane, a volatile anesthetic that is thought to facilitate GABAA neurotransmission, prevents MK-801-induced neurotoxicity.
In the present study, two additional anesthetic agents, isoflurane and propofol, were evaluated for their ability to prevent MK-801 neurotoxicity. Isoflurane is an agent with anesthetic properties simi lar to those of halothane, but with fewer untoward side effects, especially in a neurosurgical setting (Ste vens and Kingston, 1992) . Propofol (2,6-diisopropyl phenol) is a well-tolerated intravenously (i.v.) admin istered anesthetic, which has been used widely in human anesthesia in the past decade. Both isoflurane and propofol are thought to act by a mechanism in volving GABAA receptors (Nakahiro et ai., 1989; Hara et ai., 1993) .
MATERIALS AND METHODS
Adult female Sprague-Dawley rats (weight 290-320 g) were used for all experiments. MK-801 (dizocilpine) (Re search Biochemicals Incorporated, Natrick, MA, U.S.A.) was the NMDA antagonist used in all experiments. The general design of experiments was to administer MK-801 in a subcutaneous (s.c.) dose (0.5 mg/kg) that consistently induces a specific pattern and degree of cerebrocortical damage and to determine whether administration of either isoflurane or propofol together with MK-801 would modify the neurotoxic reaction.
For the isoflurane experiments, both control and experi mental rats received MK-801 (0.5 mg/kg, s.c.); experimental rats were additionally exposed to isoflurane at various con centrations and according to several time schedules. Isoflurane vapor was administered through a nose cone at an air flow of 2 Umin. A newly calibrated isofturane vapor izer (Ohio Medical Products, Madison, WI, U.S.A.) was utilized so that the dialed concentration closely corre sponded to the percent of isoflurane vapor actually admin istered.
For the propofol experiments, both control and experi mental rats received MK-801 (0.5 mg/kg, s.c.); experimental rats additionally received propofol (Zeneca Pharmaceuti cals, Wilmington, DE, U.S.A.) i.v. through a tail vein. At 15 min before administration of MK-801, propofol was given in an i.v. bolus dose (20 mg/kg), and this was followed by a steady i.v. infusion of propofol at one of several doses and according to one of several time schedules. The i.v. infusion was delivered via a 24-guage angiocath connected to a syringe pump (Sage Model 352 pump, Orion Research Incorporated, Boston, MA, U.S.A.) that administered the desired infusion rate (calculated as mg/kg/h).
The duration of treatment in the above experiments var ied from 4 to 12 h. At the termination of the experiment, the rats were deeply anesthetized with pentobarbital and killed by perfusion through the left cardiac ventricle with a phosphate-buffered fixative solution containing 4% para formaldehyde and 1.5% glutaraldehyde. After the perfu sion, the brains were removed from the skull and cut trans versely into I-mm thick slices. The slices were post-fixed in 1 % osmium tetroxide, dehydrated in ethanol, cleared in toluene, and embedded in araldite. Sections were cut Ip,m thick using 0.5-in wide glass knives on a Sorvall MT-2B 0.5-in ultratome. Sections were stained for light microscopic evaluation with a mixture of methylene blue and azure II. The severity of the neurotoxic reaction was assessed by counting the number of vacuolated neurons present in sec tions cut through the PC/RS cortex at a specific rostrocau dal level (6 mm caudal to bregma), where the toxic reaction is known to be maximally expressed.
RESULTS
In the isoflurane experiments, we found that pre vention of vacuole formation depends on the relative timing of the isoflurane and MK-801 treatments. When isoflurane was administered for 1 h (1.5-2.0% inhaled concentration) and then discontinued imme diately prior to MK-801 treatment, the number of vacuolated neurons in the PClRS cortex 4 h after MK-801 was similar to that in animals treated with MK-801 alone. In contrast, if isoflurane was adminis tered 15 min prior to MK-801 and continuously there after until death 4 h later, there were no vacuolated neurons in the PClRS cortex (Fig. 1) .
In separate experiments, isoflurane blockade of MK-801-induced vacuolization was found to be dose dependent. When isoflurane was administered con tinuously from the time of MK-80l treatment to the time of death 4 h later, the minimum dose required for complete protection was 1% inhaled isoflurane ( Fig. 2) .
In order to assess the effects of propofol on NMD A antagonist neurotoxicity, all rats received propofol The minimum dose for complete protection was 1 % inhaled isoflurane (n = 8-10 rats per treatment group).
in an initial i.v. bolus dose of 20 mg/kg, then received a continuous i.v. infusion of propofol at one of several doses ranging from 5 to 20 mg/kg/h (from light seda tion to general anesthesia, respectively). In these dose-response studies, all rats received MK-801 15 min after initiation of the continuous infusion of propofol and all animals were killed 4 h later for histological evaluation of the brain. At a dose of 5 mg/kg/h, the number of vacuolated PClRS neurons was reduced to <40% that in rats treated with MK-801 alone. At doses of 27.5 mg/kg/h, the vacuole reaction was essentially completely prevented (Fig.   3 ). The histological appearance of the PClRS cortex 4 h after MK-801 with or without propofol (20 mg/ kg/h) is illustrated in Fig. 4 . To study the time course of propofol protection against MK-801 neurotoxicity, we first studied the time course of MK-801's neurotoxic action and found that a single dose of MK-801 (0.5 mg/kg) induces vacuolization of PC/RS neurons that is detectable in 2 h, is maximally expressed in the 4-8 h interval, and gradually declines thereafter to become essentially undetectable 18 h following treatment (Fig. 5 ).
This time course profile for MK-801 neurotoxicity suggested the possibility that blockade of the neuro toxic process for the first 4 h after MK-801 treatment might not be adequate to completely prevent the neurotoxic reaction. Additional experiments were undertaken to address this issue. The standard s.c. dose of MK-801 (0.5 mg/kg) was co-administered with an i.v. bolus (20 mg/kg) of propofol followed by continuous propofol infusion of 20 mg/kg/h for 4 h. (Fig. 6) , However, brains examined at 8 h (4 h after stopping the propo fol infusion) showed only a partial protective effect (59% as many vacuolated neurons as MK-801 con troIs). Animals that lived 8 h after stopping the propo fol infusion had the same number of vacuolated neu rons as did MK-801 controls, but this merely reflected the fact that the reaction in both experimental and control animals had largely subsided by this time.
In an additional experiment, we attempted to de termine how much protection could be achieved by increasing the duration of propofol infusion to 8 h with the same dose of propofol (20 mg/kg/h) utilized in the previous experiment. However, this dose was lethal to a high percent of animals in the 5-7 h infusion interval. Therefore, we conducted these experiments with lower doses of propofol (7.5 and 10 mg/kg/h). When propofol was infused for 8 h at 7.5 mg/kg/h and the brains examined immediately, there were 17% as many vacuolated neurons as in controls (Fig. 7) . If the animals were killed 4 h later (12 h after MK-801), there were -60% as many vacu olated neurons as in corresponding control brains. When propofol was infused for 8 h at 10 mg/kg/h and the brains examined immediately, there were no vaculated neurons; if animals were killed 4 h later (12 h after MK-801), there were -60% as many vacu- The minimum dose for complete protection was 7.5 mg/kg/h, which is considered a low sedative dose in rats (n = 8-10 rats per treatment group). Rats were treated with MK-801 alone (dotted lines) or with MK-801 plus an i.v. propofol infusion (20 mg/kg bolus followed by 20 mg/kg/h) for 4 h. Animals killed immediately after the propofol infusion was stopped had no PC/RS vacuolated neurons. If the animal was killed 4 h after the infusion was stopped, the vacuo lated neuron count was 59% of that for MK-801 controls; if the animal was killed 8 h after the infusion was stopped, the vacuo lated neuron count was the same as for MK-801 controls (n = 8-10 rats per treatment group). V. JEVTO VIC-TODORO VIC ET AL. olated neur,ons as in corresponding controls (Fig. 8) .
In an additional experiment, propofol was infused for 12 h at 10 mg/kg/h and the animals killed immedi ately or 6 h later; no vacuolated neurons were found at either time (Fig. 9) . When 7.5 or 10 mg/kg/h infusion rates were used, animals appeared sedated but had positive corneal and eye lid reflexes, and readily responded to paw pinch. After discontinuation of the infusion, animals were fully awake within 20 min and had a positive righting reflex.
DISCUSSION
In these experiments, we demonstrated that two widely used general anesthetics, isoflurane and pro pofol, can prevent the powerful NMDA antagonist, MK-801, from injuring cerebrocortical neurons. In recent years, we have been intensively studying the mechanism underlying MK-801 neurotoxicity. There is extensive evidence (reviewed in Olney and Farber, 1995) that this type of neurotoxicity is mediated by a disinhibition mechanism in which GABAergic neu rons are inactivated by blockade of the NMDA re ceptors that are present on these neurons. An injuri ous excitotoxic process is thereby unleashed upon cerebrocortical neurons. Drugs that act at GABAA receptors to restore inhibitory tone (e.g., benzodiaze pines, barbiturates, and halothane) prevent unleash ing of excitotoxic activity and thereby protect cere brocortical neurons from inury (Olney et al., 1991; Ishimaru et al., 1995) . We propose that this is the mechanism that mediates the neuroprotective actions of isoflurane and propofol since both agents are known to act at GABAA receptors to augment GABAergic neurotransmission (Nakahiro et al., 1989; Hara et al., 1993; Franks and Lieb, 1994) .
Our data indicate that in order to completely pre vent expression of MK-801 neurotoxicity, isoflurane or propofol must be administered continuously for 8-12 h after MK-801 administration, i.e., for the en tire period of time that MK-801 is active in the brain. This is because the duration of action of these anes thetic agents in the brain is very brief compared to the very long duration of action of MK-801 (Adams et aI., 1980; Hucker et aI., 1982; Stevens and King ston, 1992) .
Although MK-801 is the agent used in most ani mals experiments pertaining to NMDA antagonist neurotoxicity, it is known that most, if not all, NMD A antagonists that effectively block passage of ion cur rents through NMDA receptors mimic the neurotoxic action of MK-801. For example, all agents that act at the phencyclidine (PCP) recognition site within the NMDA receptor ion channel (PCP, MK-801, ke tamine, and tiletamine) and those that act at the glutamate recognition site outside the NMDA ion channel (CPP, CPP-ene, and CGS 19755) induce this neurotoxic reaction (Olney et aI., 1989; Olney et aI., 1991; Hargreaves et aI., 1993) . In addition, although PCP and ketamine are the NMDA antagonists most extensively studied for their psychotomimetic actions (Domino and Luby, 1962; Reich and Silvay, 1989) , f recent human clinical trials with CPP, CPP-ene, and CGS 19755 have revealed that all three of these agents trigger the same type of psychotic reactions as do PCP and ketamine (Kristensen et aI., 1992; Herrling, 1994; Grotta, 1994; Muir and Lees, 1995) . In view of evidence from human studies that GABAergic agents (benzodiazepines and barbitu rates) suppress the psychotomimetic actions of NMD A antagonists (Magbagbeola and Thomas, 1974; Reich and Silvay, 1989) , it seems likely that isoflurane and propofol may also have this beneficial property. Thus, if stroke or brain trauma patients were anesthe tized with these agents while they are being treated with an NMDA antagonist, they would not only be protected against the cerebrocortical injurious effects of the NMD A antagonist but also psychotic reactions. The patient would sleep comfortably while under NMDA antagonist treatment and then would awaken without experiencing an "emergence" psychosis.
Although isoflurane is very effective in controlling MK-801 neurotoxicity and could easily be utilized in the operating room, the complicated setup required for isoflurane administration may preclude its use in an intensive care setting (e.g., for management of stroke or brain trauma); in these situations, propofol might be ideal since it has been widely used for long term sedation in critically ill patients and offers quick onset of action and prompt recovery after continuous infusion is discontinued (Beller et aI., 1988; Bailie et aI., 1992) . The level of anesthesia could be controlled from very light sedation to deep sleep. Our study indicates that sedative doses of propofol are as effec tive as high (general anesthetic) doses in blocking neurotoxicity. The doses used in the present experi ments are substantially higher than would be used in a human clinical setting due to the interspecies differences in the pharmacokinetics of propofol. For example, an anesthetic dose of propofol is 3-6 mg/ kg/h in humans (Fragen and Avram, 1992) whereas 60 mg/kg/h is required to achieve a comparable level of anesthesia in the rat (Shyr et aI., 1995; Yang et al., 1995) .
Unlike halothane, which is contraindicated for acute brain injury patients because it increases intra cranial pressure, isoflurane and propofol are consid ered favorable for such patients (Madsen et aI., 1987; Pinaud et aI., 1988) . Both agents decrease the cere bral metabolic rate and cerebral metabolic require ments for oxygen. In addition, propofol causes ce rebral vasoconstriction and thereby decreases intra cranial pressure (Herre gods et aI., 1989; Plainer et aI., 1989; Weinstabl et aI., 1990) . If given in high doses, propofol induces an isoelectric state in the brain (so-called burst suppression) (Veselis et aI., 1991) and is commonly used in neurosurgery for brain protection. Unlike most GABAergic agents (Al quander, 1978) , propofol has a very short duration of action that allows rapid recovery from anesthesia and early warning of mental status deterioration (Cockshott, 1985) ; in addition, propofol has been ad ministered by continuous i.v. infusion to humans for up to several weeks without inducing tolerance, phys ical dependence, or withdrawal reactions (Borgeat et aI., 1994) .
Recent studies (Yamakura et aI., 1995) suggest that propofol, in addition to its action at GABAA receptors, may exert a weak blocking action at NMDA receptor channels as expressed in Xenopus oocytes. Thus, if used together with another more potent NMDA antagonist in the treatment of stroke or brain trauma, propofol may enhance the degree of NMDA receptor blockade, thereby maximizing neuroprotection while preventing both the neuro toxic and psychotomimetic side effects that would otherwise accompany such blockade.
In conclusion, isoflurane and propofol may be suit able agents for use with an NMDA antagonist to enable the NMDA antagonist to be used more safely in the therapeutic management of acute brain in jury syndromes.
